All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Arnon Nagler, Vice Chair of the Acute Leukaemia Working Party of the EBMT, and Professor of Medicine at Tel Aviv University, Tel Aviv, IL. We asked, Is MRD testing for AML being performed extensively in EBMT transplant centers?
Is MRD testing for AML being performed extensively in EBMT transplant centers?
To answer this question, information from a survey performed across transplant centers in Europe was used. Here, Arnon Nagler discusses the importance of measurable residual disease (MRD) in predicting the outcome of transplantation in patients with AML. There are three main methods for assessing MRD: multiparametric flow cytometry, polymerase chain reaction, and next generation sequencing.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox